ClinicalTrials.gg
CompletedNCT05203237Updated Feb 17, 2025

Phase 1 Study to Evaluate the Safety and Tolerability of VK2735

A Phase 1 interventional study of VK2735 and Placebo in Weight Loss and NASH, sponsored by Viking Therapeutics, Inc.. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-17.

Sponsored by Viking Therapeutics, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Weight Loss with a site in Australia — 4 open to participants now, 4 under way, 2 of them phase 3. Weight Loss · Australia.

Enrollment
10th of 14
92 · median 123
Started
2021
with 1 other
Phase 1
2 of 14
1 open now
Registered
8th of 14
by date
Lead sponsor
1 of 14
Viking Therapeutics, Inc.

Among the 14 studies in Weight Loss with a site in Australia, this one is the 10th largest by enrollment, is one of 2 that started in 2021, is one of 2 in phase 1, and was the 8th registered.

Weight Loss

1,818 studies on the registry are indexed under Weight Loss; 296 are open to participants now.

Browse Weight Loss studies →

Open to participants now

4 of the 14 studies in Weight Loss with a site in Australia are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 199 Weight Loss studies recruiting now, 73 (37%) set no upper age limit and 109 (55%) stop at 75 or younger; 21 take children under 18; 57 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Weight Loss with a site in Australia, or all of them as a file.
02

Study summary

This is a Phase 1, randomized, double-blind, placebo-controlled single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VK2735 in healthy adults and otherwise healthy adults who have an increased body mass index (BMI).

Read the detailed description

This study comprises 3 parts:

Part A (Single Ascending Dose [SAD]) will be conducted to assess the safety, tolerability, and PK profile in healthy participants following 1 single SC injection of VK2735 or VK2735 matching placebo (SAD Cohort 1 through SAD Cohort 6).

Part B (Multiple Ascending Dose [MAD]) will be conducted to assess the safety, tolerability, PK and PD profile in otherwise healthy participants who have an increased BMI following single SC injections of VK2735 or matched placebo administered once weekly for 4 consecutive weeks (MAD Cohort 1 through MAD Cohort 5).

Part C (Multiple Ascending Dose [MAD], PO) will be conducted to assess the safety, tolerability, PK and PD profiles in otherwise healthy, but obese, participants who have a BMI ≥30 kg/m2 following daily oral administration of VK2735 or matched placebo administered for 28 consecutive days (MAD-PO Cohort 1 through MAD-PO Cohort 4, with optional additional cohorts)

Safety Review Committee (SRC) meetings will be held prior to dose escalation for Part A (SAD), Part B (MAD), and Part C (MAD-PO) cohorts in the study. The decisions on dose escalation will be based on safety and laboratory data from each cohort.

03

Conditions studied

  • Weight Loss
  • NASH

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must be capable of giving signed

Participants must be medically healthy, with no significant medical history, have no abnormalities on physical examination at Screening and/or before administration of the initial dose of IP in the opinion of the Investigator

Participant body weight must have been stable (no change greater than 5%) for a minimum 8 weeks prior to Screening

Willing and able to comply with scheduled visits, treatment plan, laboratory tests and other clinical study procedures

Willing to comply with requirements

Exclusion criteria

Exclusion Criteria:

Participants with any level of disease or organ system dysfunction as identified during physical examination, medical history or laboratory testing, as assessed by the PI

Any surgical or medical condition (active or chronic) that may interfere with IP distribution, metabolism, excretion, or drug absorption

Participants may be excluded from the study if they have conditions that might compromise safety or other endpoints in the study as judged by the Sponsor (or designee) or Investigator

History or presence of acute or unstable cerebrovascular (stroke), hepatic, renal, gastrointestinal, pulmonary, immunological, endocrine, diabetes, hematological, oncological, or central nervous disorder that in the opinion of the Investigator would pose a significant risk for the participant

Use of any drug or product, or participation in an investigational drug study within 30 days prior to dosing or 5 half-lives of the drug (whichever is longest)

Active smoker and/or user of nicotine-containing products unless the participant agrees to discontinue smoking/use of nicotine-containing products from 2 weeks before first IP dose administration through to study completion, including the Follow-up period

Have serum triglycerides > 5.65 mmol/L (500 mg/dL) at Screening

Positive serology for surface antigen (HBsAg), antibodies, or

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
92 participants (actual)

Study arms

  • Placebo comparator
    Placebo (Part A)

    Placebo administered SC once in healthy participants

    Biological: Placebo

  • Experimental
    VK2735 (Part A)

    Escalating doses of VK2735 administered subcutaneously (SC) once in healthy participants.

    Biological: VK2735

  • Placebo comparator
    Placebo (Part B)

    Placebo administered SC once weekly for four weeks in healthy participants

    Biological: Placebo

  • Experimental
    VK2735 (Part B)

    Escalating doses of VK2735 administered subcutaneously (SC) once weekly in healthy participants.

    Biological: VK2735

  • Placebo comparator
    VK2735 (Part C )

    Placebo administered orally daily for 28 days in healthy participants

    Drug: VK2735 Placebo

  • Experimental
    VK2735 (Part C)

    Escalating doses of VK2735 administered daily (PO) in healthy participants.

    Drug: VK2735 Drug

Interventions

  • BiologicalVK2735

    Administered SC

  • BiologicalPlacebo

    Administered SC

  • DrugVK2735 Placebo

    Administered orally

  • Administered orally

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs) and treatment-emergent serious AEs (TESAEs)

    To evaluate the safety and tolerability of single doses of subcutaneous injections of VK2735 in healthy participants

    Time frame: 8 days

Secondary outcomes

  1. Evaluate the Pharmacokinetic profile of VK2735

    Pharmacokinetic profile of VK2735 by measuring peak plasma concentration (Cmax)

    Time frame: 29 days

07

Study locations

1 site
  • Viking Clinical Site
    Adelaide, South Australia 5000, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Nov 2024, 34 months.

Of 24 phase 1 interventional studies under Weight Loss, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 25. This study's 34 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2022
First posted
Jan 24, 2022
StartActual
Dec 14, 2021
Primary completionActual
Nov 4, 2024
CompletionActual
Dec 3, 2024
Last update
Feb 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05203237
Responsible party
Sponsor
First posted
Jan 24, 2022
Start date
Dec 14, 2021
Primary completion
Nov 4, 2024
Completion
Dec 3, 2024
Last update
Feb 17, 2025

Study contacts

Marianne Mancini
study director · Viking Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VK2735

Start the discussion